Medsenic Alters Phebra Contract For OATO

In May 2021, Medsenic and Phebra made a deal to license OATO. A picture by Markus Spiske on Unsplash shows this.

BioSenic's affiliate, Medsenic, has changed the license deal with Phebra for the oral formulation of arsenic trioxide.

Phebra and Medsenic made deals for OATO. It happened in May 2021. These deals cover licensing, marketing, and supply.

This product can treat various conditions. Some of these conditions include systemic sclerosis, graft versus host disease, systemic lupus erythematosus 151,central nervous system inflammatory diseases that come with multiple sclerosis, and infectious diseases that are connected to Covid-19.

Professor François Rieger, the CEO of BioSenic, said that they are happy about the collaboration between Phebra and Medsenic. They worked together to create clinical batches for the Phase III trial of the oral medication. This trial is part of an exclusive license agreement between Phebra and Medsenic.

New inventions in the oral ATO treatment and a modified license will speed up FDA approval. An IND submission is necessary, followed by selecting centers and recruiting patients.

Before 31 May 2024, Medsenic must start a clinical study for the licence agreement to be valid.

Medsenic's territories and commercial terms are being studied by BioSenic Group and Phebra for potential expansion.